Although differences in results between a commercial anti-TIF1γ assay (Euroline) and an in-house IB previously validated against IP are not significant for patients with DM and CAM, agreement in the absence of a definitive DM diagnosis is poor. This evidence concerns the gene TRIM33 and dermatomyositis.